Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Apricus Biosciences has received a Notice of Allowance (NoA) from the Israeli Patent Office to grant a patent for the company's development of a topical cream utilizing vasoactive prostaglandin E to treat premature ejaculation (PE).
Subscribe to our email newsletter
The patent, entitled, ‘Compositions and Methods for the Treatment of Premature Ejaculation,’ will provide Israeli patent protection until March 2024, once it is issued.
Apricus Bio’s male sexual dysfunction field utilizes its proprietary NexACT technology, which includes its Vitaros product to treat erectile dysfunction (ED), among others.
Vitaros is a topical cream that incorporates alprostadil, a vasodilator currently marketed by other companies as an injectable product or an intra-urethral insert.
Apricus Bio chairman, president and CEO Bassam Damaj said the company is glad with the allowance of this patent in Israel for the use of vasoactive prostaglandin E to treat PE.
"This patent includes the same pharmaceutical composition as found in Apricus Bio’s Vitaros product for ED combined with a local anesthetic and represents our tenth patent granted in that country on our NexACT technology," Damaj added.